Enterprise Value

12.03M

Cash

6.779M

Avg Qtr Burn

-6.926M

Short % of Float

2.93%

Insider Ownership

3.96%

Institutional Own.

58.04%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
MT-8421 Details
Cancer, Solid tumor/s

Phase 1

Data readout

MT-6402 Details
Solid tumor/s, Cancer

Phase 1

Data readout

MT-3724 with GEMOX (CD20) Details
DLBCL (Diffuse large B-cell lymphoma)

Failed

Discontinued

MT-3724 (CD20) with Lenalidomide Details
DLBCL (Diffuse large B-cell lymphoma)

Failed

Discontinued

MT-3724 (CD20) monotherapy Details
DLBCL (Diffuse large B-cell lymphoma)

Failed

Discontinued

MT-5111 Details
Breast cancer, Cancer

Failed

Discontinued

MT-0169 (TAK-169) (CD38) Details
Multiple myeloma, Extramedullary myeloma

Failed

Discontinued